Literature DB >> 17997138

Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+ T-cell activation.

Michael A Kolber1, María O Saenz, Tom J Tanner, Kristopher L Arheart, Savita Pahwa, Huanliang Liu.   

Abstract

A significant proportion of HIV-1-infected individuals on suppressive HAART regimens do not reconstitute CD4 counts well. If viral reservoirs persist and impact on CD4 reconstitution in a percentage of cases then addition of another antiretroviral agent could further suppress these reservoirs resulting in enhanced CD4 recovery. To evaluate this possibility, we studied the effect of adding abacavir to a chronically suppressive NNRTI containing HAART regimen for 8 patients on their CD4 count and expression of activation markers. Over the first 24 weeks of intensification, CD4 counts increased significantly (p=0.028). This increase continued after a year in follow-up with a significant rate of change in CD4 T-cells of 0.959+/-1.27 per week. In addition, during intensification changes in the percentage of CD38+CD8+ T-cells over time were significantly negatively correlated with changes in CD4 cell number over time above increases predicted without intensification (r(2)=0.716, p=0.008). These data support the possibility that in certain cases where suboptimal CD4 reconstitution occurs that intensification of the regimen can impact immunologic parameters.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17997138     DOI: 10.1016/j.clim.2007.10.002

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  10 in total

1.  Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.

Authors:  Christopher Vinnard; Shruthi Ravimohan; Neo Tamuhla; Vijay Ivaturi; Jotam Pasipanodya; Shashikant Srivastava; Chawangwa Modongo; Nicola M Zetola; Drew Weissman; Tawanda Gumbo; Gregory P Bisson
Journal:  Br J Clin Pharmacol       Date:  2016-12-09       Impact factor: 4.335

2.  Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.

Authors:  Gregory Q Del Prete; Rebecca Shoemaker; Kelli Oswald; Abigail Lara; Charles M Trubey; Randy Fast; Douglas K Schneider; Rebecca Kiser; Vicky Coalter; Adam Wiles; Rodney Wiles; Brandi Freemire; Brandon F Keele; Jacob D Estes; Octavio A Quiñones; Jeremy Smedley; Rhonda Macallister; Rosa I Sanchez; John S Wai; Christopher M Tan; W Gregory Alvord; Daria J Hazuda; Michael Piatak; Jeffrey D Lifson
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

3.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

4.  EBV-specific CD8+ T cells from asymptomatic pediatric thoracic transplant patients carrying chronic high EBV loads display contrasting features: activated phenotype and exhausted function.

Authors:  Camila Macedo; Steven A Webber; Albert D Donnenberg; Iulia Popescu; Yun Hua; Michael Green; David Rowe; Louise Smith; Maria M Brooks; Diana Metes
Journal:  J Immunol       Date:  2011-04-01       Impact factor: 5.422

5.  Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

Authors:  Steven A Yukl; Amandeep K Shergill; Kenneth McQuaid; Sara Gianella; Harry Lampiris; C Bradley Hare; Mark Pandori; Elizabeth Sinclair; Huldrych F Günthard; Marek Fischer; Joseph K Wong; Diane V Havlir
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

6.  Constitutive activation of phosphatidylinositol 3-kinase signaling pathway down-regulates TLR4-mediated tumor necrosis factor-alpha release in alveolar macrophages from asymptomatic HIV-positive persons in vitro.

Authors:  Souvenir D Tachado; Xin Li; Katharine Swan; Naimish Patel; Henry Koziel
Journal:  J Biol Chem       Date:  2008-09-30       Impact factor: 5.157

7.  CD4:CD8 ratio and CD8+ cell count for prognosticating mortality in HIV-infected patients on antiretroviral therapy.

Authors:  Jeffrey Daniel Jenks; Martin Hoenigl
Journal:  J Lab Precis Med       Date:  2018-02-02

8.  Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection.

Authors:  R Brad Jones; Lishomwa C Ndhlovu; Jason D Barbour; Prameet M Sheth; Aashish R Jha; Brian R Long; Jessica C Wong; Malathy Satkunarajah; Marc Schweneker; Joan M Chapman; Gabor Gyenes; Bahareh Vali; Martin D Hyrcza; Feng Yun Yue; Colin Kovacs; Aref Sassi; Mona Loutfy; Roberta Halpenny; Desmond Persad; Gerald Spotts; Frederick M Hecht; Tae-Wook Chun; Joseph M McCune; Rupert Kaul; James M Rini; Douglas F Nixon; Mario A Ostrowski
Journal:  J Exp Med       Date:  2008-11-10       Impact factor: 14.307

9.  CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART.

Authors:  Rafael Sauter; Ruizhu Huang; Bruno Ledergerber; Manuel Battegay; Enos Bernasconi; Matthias Cavassini; Hansjakob Furrer; Matthias Hoffmann; Mathieu Rougemont; Huldrych F Günthard; Leonhard Held
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

10.  Antiretroviral therapy suppressed participants with low CD4+ T-cell counts segregate according to opposite immunological phenotypes.

Authors:  Josué Pérez-Santiago; Dan Ouchi; Victor Urrea; Jorge Carrillo; Cecilia Cabrera; Jordi Villà-Freixa; Jordi Puig; Roger Paredes; Eugènia Negredo; Bonaventura Clotet; Marta Massanella; Julià Blanco
Journal:  AIDS       Date:  2016-09-24       Impact factor: 4.177

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.